General Information of Drug (ID: DMFKQ1W)

Drug Name
T-98475 Drug Info
Synonyms
T 98475; T-98475; UNII-F1KLT23O3A; 192887-28-8; F1KLT23O3A; CHEMBL71917; CHEMBL544440; 7-[(2,6-Difluorophenyl)methyl]-4,7-dihydro-2-[4-[(2-methyl-1-oxopropyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-4-oxo-thieno[2,3-b]pyridine-5-carboxylic acid 1-methylethyl ester; 199119-18-1; GTPL1184; SCHEMBL7497514; CTK8E7257; CHEBI:93085; DTXSID90432134; MolPort-023-276-465; HMS3269M21; ZINC4424097; BDBM50067485; AKOS024457145; NCGC00167759-01; Isopropyl 3-(N-benzyl-N-methylaminomethyl)-7-(2,6-difluorobenzyl)-4,7-dihydro-2-(4-i
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9874838
ChEBI ID
CHEBI:93085
CAS Number
CAS 192887-28-8
TTD Drug ID
DMFKQ1W

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gonadorelin DMAQ469 Amenorrhea GA20.0 Approved [3]
Relugolix DMK7IWL Prostate cancer 2C82.0 Approved [4]
Ganirelix DMGMB30 Ovulation dysfunction 5A80 Approved [5]
Abarelix DM5WFNP Prostate cancer 2C82.0 Approved [6]
Triptorelin DMTK4LS Infertility GB04 Approved [7]
Leuprorelin acetate DM15HAT Prostate cancer 2C82.0 Approved [8]
Nafarelin DMAHEFY Endometriosis GA10 Approved [9]
Cetrorelix DMFD9Q6 Ovarian stimulation LB45.1 Approved [10]
Elagolix sodium DMRDUC0 Endometriosis GA10 Approved [11]
Degarelix DM3O8QY Prostate cancer 2C82.0 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gonadotropin-releasing hormone receptor (GNRHR) TT8R70G GNRHR_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1184).
2 Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem. 2008 Jun 26;51(12):3331-48.
3 Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5 Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44.
8 Clinical pipeline report, company report or official report of Takeda (2009).
9 Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45.
10 Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33.
11 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
12 Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60.